bearish

Yunkang Group

Pre-IPO Yunkang Group - Lack of New Growth Point

The COVID-19 business isn't enough to support Yunkang's future development. It also lacks new growth points. It is recommended to calculate its future valuation by excluding COVID-19 related projects.

Equity Capital Markets
172 Views, 01 Mar 2022 08:47
SUMMARY(Sign Up to Access)
or
Full Insight
(Paid Plans Only)
Discussions
(Paid Plans Only)
WHAT’S TRENDING
Insights
  • Trending
  • Latest
Logo
Top Quartile
Xinyao (Criss) Wang
HK/China Healthcare Analyst (ex-Fosun Pharma)
ChinaHealth CareEquity Bottom-UpThematic (Sector/Industry)
Price Chart(Sign Up to Access)
analytics-chart
x